MCID: OVR078
MIFTS: 65

Ovarian Cancer, Somatic malady

Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases categories

Aliases & Classifications for Ovarian Cancer, Somatic

About this section

Aliases & Descriptions for Ovarian Cancer, Somatic:

Name: Ovarian Cancer, Somatic 46 9
Ovarian Cancer 8 42 10 44 32 2
Ovarian Carcinoma 8 42 44 61
Adenocarcinoma, Ovarian, Somatic 46 9
Ovarian Neoplasm 8 61
Ovary Neoplasm 8 22
Ovarian Cancer Ovarian Cancer, Epithelial, Included 46
Primary Malignant Neoplasm of Ovary 61
 
Ovarian Cancer, Susceptibility to 9
Malignant Neoplasm of Ovary 61
Ovarian Carcinoma, Somatic 46
Malignant Tumour of Ovary 8
Epithelial Ovarian Cancer 61
Malignant Ovarian Tumor 8
Primary Ovarian Cancer 8
Tumor of the Ovary 8


Classifications:



Summaries for Ovarian Cancer, Somatic

About this section
MedlinePlus:32 The ovaries are part of the female reproductive system. they produce a woman's eggs and female hormones. each ovary is about the size and shape of an almond. cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. the sooner ovarian cancer is found and treated, the better your chance for recovery. but ovarian cancer is hard to detect early. women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. then it is hard to treat. symptoms may include a heavy feeling in the pelvis pain in the lower abdomen bleeding from the vagina weight gain or loss abnormal periods unexplained back pain that gets worse gas, nausea, vomiting, or loss of appetite to diagnose ovarian cancer, doctors do one or more tests. they include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. treatment is usually surgery followed by chemotherapy. nih: national cancer institute

MalaCards based summary: Ovarian Cancer, Somatic, also known as ovarian cancer, is related to breast cancer and fallopian tube cancer, and has symptoms including autosomal dominant inheritance, abnormality of metabolism/homeostasis and breast carcinoma. An important gene associated with Ovarian Cancer, Somatic is CTNNB1 (catenin (cadherin-associated protein), beta 1, 88kDa), and among its related pathways are Adherens junction and Nectin adhesion pathway. The drugs cyclophosphamide and doxorubicin hydrochloride liposome and the compounds sodium bisulfite and everolimus have been mentioned in the context of this disorder. Affiliated tissues include the ovary, ovary and testes, and related mouse phenotypes are no phenotypic analysis and skeleton.

Disease Ontology:8 A female reproductive organ cancer that is located in the ovary.

CDC:2 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

OMIM:46 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with... (167000) more...

Related Diseases for Ovarian Cancer, Somatic

About this section

Diseases related to Ovarian Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 344)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer31.6ERBB2, BRCA1
2fallopian tube cancer31.2BRCA1
3malignant mixed mullerian tumor31.0ERBB2, KRAS, CTNNB1
4lynch syndrome30.9BRCA1, KRAS
5pancreatic cancer30.4CDH1, KRAS, AKT1
6li-fraumeni syndrome30.4BRCA1, ERBB2
7prostate cancer30.4AKT1, ERBB2, CDH1, CTNNB1
8colorectal cancer30.4CTNNB1, CDH1, KRAS, AKT1, PIK3CA
9cystadenoma30.3BRCA1, KRAS
10lung cancer30.2KRAS, ERBB2, PIK3CA
11endometrial cancer30.2ERBB2, KRAS, CDH1, CTNNB1
12cowden disease30.2BRCA1, PIK3CA
13colon adenocarcinoma30.1KRAS, CDH1, CTNNB1
14melanoma29.9PIK3CA, AKT1, KRAS, CDH1, CTNNB1
15adenocarcinoma29.9PIK3CA, BRCA1, AKT1, ERBB2, KRAS, CDH1
16adenomatous polyposis coli29.9BRCA1, KRAS, CDH1, CTNNB1
17leukemia29.8KRAS, AKT1, PARK2, BRCA1, PIK3CA
18adenoma29.8CTNNB1, CDH1, KRAS, BRCA1
19retinoblastoma29.4PIK3CA, BRCA1, PARK2, AKT1, ERBB2, KRAS
20endodermal sinus tumor10.9
21hereditary breast ovarian cancer10.9
22peritonitis10.9
23endotheliitis10.9
24hypoxia10.7
25endometriosis10.7
26mixed germ cell tumor10.7
27prostatitis10.6
28brca2 hereditary breast and ovarian cancer10.6
29neuroectodermal tumor10.6
30sertoli cell tumor10.6
31cervicitis10.5
32thrombocytosis10.5
33brca1 hereditary breast and ovarian cancer10.5
34gastric cancer risk after h. pylori infection10.5CDH1
35adenomatoid tumor10.5
36insulin-like growth factor i10.5
37mesothelioma10.5
38ovarian cyst10.4
39peritoneal carcinoma10.4
40cerebellar degeneration10.4
41paraneoplastic cerebellar degeneration10.4
42primary peritoneal carcinoma10.4
43goblet cell carcinoid10.4CDH1, CTNNB1
44ovarian brenner tumor10.4
45fibroma10.4
46amenorrhea10.4
47glomus tumor10.4
48peripheral primitive neuroectodermal tumor10.4
49malignant mixed epithelial mesenchymal tumor of the ovary10.4
50breast-ovarian cancer, familial, 210.3

Graphical network of the top 20 diseases related to Ovarian Cancer, Somatic:



Diseases related to ovarian cancer, somatic

Symptoms for Ovarian Cancer, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

167000

Clinical features from OMIM:

167000

HPO human phenotypes related to Ovarian Cancer, Somatic:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 abnormality of metabolism/homeostasis HP:0001939
3 breast carcinoma HP:0003002
4 ovarian papillary adenocarcinoma HP:0006774
5 dysgerminoma HP:0100621

Drugs & Therapeutics for Ovarian Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Doxil13 38 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
FDA Label: Doxil
Malady that Drug Treats: ovarian cancer that is refractory to other first-line therapies
Indications and Usage:13 DOXIL is an anthracycline topoisomerase II inhibitor indicated for:; Ovarian cancer (1.1); After failure of platinum-based chemotherapy.; AIDS-related Kaposi s Sarcoma (1.2); After failure of prior systemic chemotherapy or intolerance to such therapy.; Multiple Myeloma (1.3); In combination with bortezomib in patients who have not previously; received bortezomib and have received at least one prior therapy.
DrugBank Targets:11 1. DNA; 2. DNA topoisomerase 2-alpha
Mechanism of Action:13 
Target: nucleic acid; synthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action of; doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid; synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear; Reference ID: 3733596; 17 ; ; ; ; ; chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and; induction of mutagenesis and chromosomal aberrations.
2
Ethyol13 AMIFOSTINE Alza Approved December 8, 1995
FDA Label: Ethyol
Malady that Drug Treats: ovarian cancer
Indications and Usage:13 ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated with; repeated administration of cisplatin in patients with advanced ovarian cancer.; ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patients; undergoing post-operative radiation treatment for head and neck cancer, where the radiation; port includes a substantial portion of the parotid glands (see Clinical Studies).; For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin based; chemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limited; data on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings.; ETHYOL should not be administered to patients in other settings where chemotherapy can produce a; significant survival benefit or cure, or in patients receiving definitive radiotherapy, except in the; context of a clinical study (see WARNINGS).
DrugBank Targets:11 1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1; 2. Alkaline phosphatase, placental-like
Mechanism of Action:13 
Target: -
Action: -
FDA: -
3
Hycamtin13 38 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham Approved October 2007/Approved May 1996
FDA Label: Hycamtin
Malady that Drug Treats: small cell lung cancer/ ovarian cancer
Indications and Usage:13 HYCAMTIN for injection is a topoisomerase inhibitor indicated for:; metastatic carcinoma of the ovary after disease progression on or after; initial or subsequent chemotherapy. (1.1); small cell lung cancer platinum-sensitive disease in patients who; progressed after first-line chemotherapy. (1.2); combination therapy with cisplatin for Stage IV-B, recurrent, or; persistent carcinoma of the cervix which is not amenable to curative; treatment. (1.3)
DrugBank Targets:11 1. DNA topoisomerase 1; 2. DNA topoisomerase I, mitochondrial; 3. DNA
Mechanism of Action:13 
Target: topoisomerase I
Action: inhibitor
FDA: Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks.; Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these singlestrand; breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage; produced during DNA synthesis, when replication enzymes interact with the ternary complex; formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair; these double-strand breaks.
4
Lynparza13 38 OLAPARIB AstraZeneca Approved December 2014
FDA Label: Lynparza
Malady that Drug Treats: previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:13 Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as; monotherapy in patients with deleterious or suspected deleterious germline; BRCA mutated (as detected by an FDA-approved test) advanced ovarian; cancer who have been treated with three or more prior lines of chemotherapy.; (1.1); The indication is approved under accelerated approval based on objective; response rate and duration of response. Continued approval for this indication; may be contingent upon verification and description of clinical benefit in; confirmatory trials. (1 1, 14)
DrugBank Targets:11 1. Poly [ADP-ribose] polymerase 1; 2. Poly [ADP-ribose] polymerase 2; 3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:13 
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.; PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA; repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse; xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased; cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models; with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of; PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis; and cell death.

Drug clinical trials:

Search ClinicalTrials for Ovarian Cancer, Somatic

Search NIH Clinical Center for Ovarian Cancer, Somatic

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Ovarian Cancer, Somatic

About this section

Genetic tests related to Ovarian Cancer, Somatic:

id Genetic test Affiliating Genes
1 Neoplasm of Ovary22

Anatomical Context for Ovarian Cancer, Somatic

About this section

MalaCards organs/tissues related to Ovarian Cancer, Somatic:

31
Ovary, Testes, Breast

FMA organs/tissues related to Ovarian Cancer, Somatic:

14
The ovary

Animal Models for Ovarian Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Ovarian Cancer, Somatic:

35 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.7CTNNB1, CDH1, OPCML, PARK2, PIK3CA
2MP:00053908.5ERBB2, CTNNB1, AKT1, BRCA1, PARK2
3MP:00053818.4BRCA1, ERBB2, KRAS, CDH1, CTNNB1
4MP:00053718.3BRCA1, PALB2, ERBB2, KRAS, CTNNB1
5MP:00053888.2AKT1, KRAS, PARK2, BRCA1, ERBB2, CTNNB1
6MP:00028738.2ERBB2, AKT1, CDH1, BRCA1, KRAS, CTNNB1
7MP:00053758.0PIK3CA, AKT1, BRCA1, RRAS2
8MP:00053798.0PIK3CA, BRCA1, AKT1, CTNNB1, CDH1, KRAS
9MP:00053897.9AKT1, CTNNB1, CDH1, KRAS, BRCA1, PIK3CA
10MP:00053697.9BRCA1, CTNNB1, PIK3CA, KRAS, ERBB2, AKT1
11MP:00053867.7BRCA1, CTNNB1, KRAS, ERBB2, AKT1, PARK2
12MP:00053767.5BRCA1, PARK2, CDH1, PIK3CA, AKT1, KRAS
13MP:00053807.4CTNNB1, CDH1, KRAS, AKT1, PALB2, BRCA1
14MP:00053877.3BRCA1, KRAS, PIK3CA, RRAS2, AKT1, CTNNB1
15MP:00036317.2KRAS, ERBB2, CTNNB1, PARK2, PIK3CA, BRCA1
16MP:00107717.0PARK2, BRCA1, CDH1, KRAS, ERBB2, AKT1
17MP:00053846.9BRCA1, PIK3CA, AKT1, PARK2, ERBB2, KRAS
18MP:00107686.9PARK2, KRAS, BRCA1, PIK3CA, CDH1, PALB2
19MP:00020066.6PIK3CA, CTNNB1, CDH1, KRAS, ERBB2, AKT1
20MP:00053856.2PIK3CA, PARK2, RRAS2, BRCA1, PALB2, AKT1
21MP:00053786.1AKT1, ERBB2, KRAS, CDH1, PIK3CA, RRAS2

Publications for Ovarian Cancer, Somatic

About this section

Variations for Ovarian Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer, Somatic:

63
id Symbol AA change Variation ID SNP ID
1BRCA1p.Cys61GlyVAR_007757rs28897672
2BRCA1p.Cys1697ArgVAR_020702
3BRCA1p.Arg1699TrpVAR_020703
4CTNNB1p.Ser37CysVAR_017625
5CTNNB1p.Thr41IleVAR_017630
6OPCMLp.Pro95ArgVAR_055421
7PIK3CAp.His1047ArgVAR_026192

Clinvar genetic disease variations for Ovarian Cancer, Somatic:

5 (show all 34)
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_033360.3(KRAS): c.34G> A (p.Gly12Ser)single nucleotide variantPathogenic, drug responsers121913530GRCh37Chr 12, 25398285: 25398285
2PALB2NM_024675.3(PALB2): c.1050_1053delAACA (p.Thr351Argfs)deletionPathogenicrs515726060GRCh38Chr 16, 23635493: 23635496
3PIK3CANM_006218.2(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
4PIK3CANM_006218.2(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
5ERBB2NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser)single nucleotide variantPathogenicrs28933370GRCh37Chr 17, 37881378: 37881378
6AKT1NM_001014431.1(AKT1): c.49G> A (p.Glu17Lys)single nucleotide variantPathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
7NC_012920.1: m.14743A> Gsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 14743: 14743
8MT-CYBNC_012920.1: m.14753C> Tsingle nucleotide variantLikely pathogenicGRCh38Chr MT, 14753: 14753
9MT-CYBNC_012920.1: m.14784T> Csingle nucleotide variantLikely pathogenicGRCh37Chr MT, 14784: 14784
10MT-CYBNC_012920.1: m.15058C> Tsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15058: 15058
11MT-CYBNC_012920.1: m.15098A> Gsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15098: 15098
12MT-CYBNC_012920.1: m.15314G> Asingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15314: 15314
13MT-CYBNC_012920.1: m.15328A> Gsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15328: 15328
14MT-CYBNC_012920.1: m.15334C> Tsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15334: 15334
15MT-CYBNC_012920.1: m.15363A> Gsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15363: 15363
16MT-CYBNC_012920.1: m.15453T> Csingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15453: 15453
17MT-CYBNC_012920.1: m.15459C> Tsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15459: 15459
18MT-CYBNC_012920.1: m.15511T> Csingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15511: 15511
19MT-CYBNC_012920.1: m.15884G> Asingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15884: 15884
20MT-TTNC_012920.1: m.15890C> Asingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15890: 15890
21MT-TTNC_012920.1: m.15928G> Asingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15928: 15928
22MT-TTNC_012920.1: m.15932T> Gsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15932: 15932
23MT-TTNC_012920.1: m.15943T> Csingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15943: 15943
24MT-CYBNC_012920.1: m.15061A> Gsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15061: 15061
25MT-CYBNC_012920.1: m.15148G> Asingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15148: 15148
26MT-CYBNC_012920.1: m.15259C> Tsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15259: 15259
27MT-CYBNC_012920.1: m.15431G> Asingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15431: 15431
28MT-CYBNC_012920.1: m.15452C> Asingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15452: 15452
29MT-CYBNC_012920.1: m.15607A> Gsingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15607: 15607
30MT-CYBNC_012920.1: m.15670T> Csingle nucleotide variantLikely pathogenicGRCh37Chr MT, 15670: 15670
31CTNNB1NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys)single nucleotide variantLikely pathogenic, Pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
32PARK2PARK2, DELdeletionPathogenic
33OPCMLNM_001012393.1(OPCML): c.263C> G (p.Pro88Arg)single nucleotide variantPathogenicrs137852691GRCh37Chr 11, 132527098: 132527098
34RRAS2NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu)single nucleotide variantPathogenicrs113954997GRCh37Chr 11, 14316390: 14316390

Cosmic variations for Ovarian Cancer, Somatic:

6 (show all 28)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
153264EGFRovary,NS,carcinoma,adenocarcinoma3
253227EGFRovary,NS,carcinoma,adenocarcinoma3
353213EGFRovary,NS,carcinoma,adenocarcinoma3
428286EGFRovary,NS,carcinoma,adenocarcinoma3
553228EGFRovary,NS,carcinoma,adenocarcinoma3
653232EGFRovary,NS,carcinoma,adenocarcinoma3
722992EGFRovary,NS,carcinoma,adenocarcinoma3
853230EGFRovary,NS,carcinoma,adenocarcinoma3
928511EGFRovary,NS,carcinoma,adenocarcinoma3
106224EGFRovary,NS,carcinoma,adenocarcinoma3
1153224EGFRovary,NS,carcinoma,adenocarcinoma3
1253226EGFRovary,NS,carcinoma,adenocarcinoma3
1353265EGFRovary,NS,carcinoma,adenocarcinoma3
1412373EGFRovary,NS,carcinoma,adenocarcinoma3
1553266EGFRovary,NS,carcinoma,adenocarcinoma3
16775PIK3CAovary,NS,carcinoma,adenocarcinoma3
17760PIK3CAovary,NS,carcinoma,adenocarcinoma3
181668065INSRRovary,NS,carcinoma,adenocarcinoma3
19727028EP300ovary,NS,carcinoma,adenocarcinoma3
201674106CSMD3ovary,NS,carcinoma,adenocarcinoma3
2130798CTNNB1ovary,NS,carcinoma,adenocarcinoma3
221682212LIMK2ovary,NS,carcinoma,adenocarcinoma3
231677803ING1ovary,NS,carcinoma,adenocarcinoma3
241669397LRP2ovary,NS,carcinoma,adenocarcinoma3
2510662TP53ovary,NS,carcinoma,adenocarcinoma3
261681052RAB4Bovary,NS,carcinoma,adenocarcinoma3
271680748NOTCH3ovary,NS,carcinoma,adenocarcinoma3
281669654ORC2ovary,NS,carcinoma,adenocarcinoma3

Expression for genes affiliated with Ovarian Cancer, Somatic

About this section
Search GEO for disease gene expression data for Ovarian Cancer, Somatic.

Pathways for genes affiliated with Ovarian Cancer, Somatic

About this section

Pathways related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 121)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.5ERBB2, CDH1, CTNNB1
29.4CTNNB1, PIK3CA, CDH1
39.4CTNNB1, CDH1, KRAS
4
Show member pathways
VEGFR1 specific signals36
9.4PIK3CA, CTNNB1, AKT1
59.3PIK3CA, AKT1, CDH1
69.3CDH1, AKT1, PIK3CA
7
Show member pathways
9.3ERBB2, AKT1, PIK3CA
89.3AKT1, KRAS, CTNNB1
99.3BRCA1, AKT1, CTNNB1
109.2AKT1, KRAS, ERBB2
119.2CTNNB1, ERBB2, AKT1, CDH1
129.1KRAS, PIK3CA, AKT1
13
Show member pathways
9.1AKT1, KRAS, PIK3CA
14
Show member pathways
IFN-gamma pathway36
9.1AKT1, BRCA1, PIK3CA
15
Show member pathways
Development VEGF signaling via VEGFR2 generic cascades59
9.1AKT1, PIK3CA, BRCA1
169.1PIK3CA, CDH1, CTNNB1, AKT1
179.1CTNNB1, CDH1, AKT1, PIK3CA
18
Show member pathways
Translation Non genomic rapid action of Androgen Receptor59
9.0PIK3CA, AKT1, ERBB2, CTNNB1
199.0CDH1, AKT1, ERBB2, PIK3CA
208.8CTNNB1, KRAS, AKT1, PIK3CA
21
Show member pathways
Cytoskeleton remodeling FAK signaling59
Development Endothelin 1 EDNRA transactivation of EGFR59
8.8PIK3CA, KRAS, CTNNB1, AKT1
22
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
8.8KRAS, ERBB2, AKT1, PIK3CA
23
Show member pathways
Transcription Receptor mediated HIF regulation59
Development CNTF receptor signaling59
Class IB PI3K non-lipid kinase events36
ErbB2/ErbB3 signaling events36
Development Growth hormone signaling via PI3K AKT and MAPK cascades59
Translation Regulation activity of EIF259
Regulation of lipid metabolism Insulin signaling generic cascades59
Transcription PPAR Pathway59
Cell adhesion PLAU signaling59
Translation Regulation activity of EIF4F59
8.8ERBB2, KRAS, PIK3CA, AKT1
24
Show member pathways
8.8ERBB2, AKT1, PIK3CA, KRAS
25
Show member pathways
8.8KRAS, ERBB2, PIK3CA, AKT1
26
Show member pathways
Prolactin Signaling Pathway36
Development Prolactin receptor signaling59
Leptin signaling pathway36
8.8PIK3CA, AKT1, ERBB2, KRAS
27
Show member pathways
8.8PIK3CA, AKT1, ERBB2, KRAS
28
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
8.8AKT1, PIK3CA, ERBB2, KRAS
29
Show member pathways
8.7CTNNB1, CDH1, AKT1, RRAS2
308.7CTNNB1, RRAS2, AKT1, CDH1
318.6KRAS, ERBB2, BRCA1, PIK3CA
32
Show member pathways
8.5KRAS, PIK3CA, AKT1, ERBB2, CTNNB1
33
Show member pathways
8.5CTNNB1, KRAS, RRAS2, AKT1
348.5AKT1, KRAS, CTNNB1, RRAS2
358.5CTNNB1, KRAS, BRCA1, AKT1, CDH1
36
Show member pathways
8.4CDH1, ERBB2, AKT1, RRAS2, CTNNB1
37
Show member pathways
8.4RRAS2, CTNNB1, CDH1, ERBB2, AKT1
38
Show member pathways
8.3KRAS, PIK3CA, AKT1, RRAS2
39
Show member pathways
Integrin-mediated cell adhesion36
Focal Adhesion36
8.2PIK3CA, AKT1, ERBB2, CTNNB1, RRAS2
408.2CDH1, PIK3CA, AKT1, KRAS, ERBB2, CTNNB1
41
Show member pathways
Signal transduction PTEN pathway59
8.2CTNNB1, CDH1, KRAS, ERBB2, PIK3CA, AKT1
42
Show member pathways
8.1AKT1, CDH1, RRAS2, BRCA1, ERBB2
438.0PIK3CA, RRAS2, AKT1, KRAS, CTNNB1
448.0BRCA1, PIK3CA, AKT1, ERBB2, CTNNB1, KRAS
45
Show member pathways
Development ERBB family signaling59
Development GDNF family signaling59
7.9CTNNB1, PIK3CA, CDH1, ERBB2, AKT1, RRAS2
46
Show member pathways
7.8RRAS2, AKT1, ERBB2, CDH1, BRCA1, CTNNB1
47
Show member pathways
7.7CTNNB1, PIK3CA, RRAS2, AKT1, KRAS, CDH1
487.7PIK3CA, RRAS2, CTNNB1, KRAS, ERBB2, AKT1
49
Show member pathways
Signaling Pathways in Glioblastoma36
7.7BRCA1, PIK3CA, AKT1, ERBB2, KRAS, CDH1
50
Show member pathways
7.5CDH1, PIK3CA, BRCA1, PARK2, AKT1, KRAS

Compounds for genes affiliated with Ovarian Cancer, Somatic

About this section

Compounds related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 109)
idCompoundScoreTop Affiliating Genes
1sodium bisulfite449.7CDH1, CTNNB1, BRCA1
2everolimus44 50 1111.6PIK3CA, ERBB2, AKT1
3celecoxib44 60 28 50 24 1114.5CDH1, CTNNB1, ERBB2, AKT1
4geldanamycin44 50 60 1112.5CTNNB1, CDH1, ERBB2, PARK2
5indole-3-carbinol449.4CTNNB1, CDH1, AKT1, BRCA1
6ag 1478449.3AKT1, ERBB2, CTNNB1, PIK3CA
7herbimycin a44 6010.3ERBB2, CDH1, AKT1, CTNNB1
8crcs449.3KRAS, CDH1, PIK3CA, CTNNB1
9nocodazole44 1110.3CDH1, AKT1, CTNNB1, BRCA1
104-hydroxytamoxifen449.3CTNNB1, AKT1, BRCA1, ERBB2
11egcg449.3ERBB2, CDH1, CTNNB1, PIK3CA
12cetuximab44 50 1111.2KRAS, CTNNB1, ERBB2
13erlotinib44 50 1111.2ERBB2, PIK3CA, KRAS, CDH1
14curcumin449.2ERBB2, CDH1, CTNNB1, AKT1
1517-(allylamino)-17-demethoxygeldanamycin449.2ERBB2, CDH1, AKT1
16resveratrol44 60 24 1112.1PIK3CA, ERBB2, BRCA1, CTNNB1
17docetaxel44 50 60 1112.1BRCA1, CDH1, ERBB2, PIK3CA
18adriamycin449.1BRCA1, ERBB2, AKT1, CDH1, CTNNB1
19mg 13244 6010.0CDH1, CTNNB1, AKT1, PARK2, BRCA1
20glycogen44 249.9CDH1, AKT1, PIK3CA, CTNNB1, PARK2
21imatinib44 50 1110.9KRAS, PIK3CA, ERBB2, CTNNB1
22p002448.9CTNNB1, CDH1, KRAS, ERBB2, BRCA1
23phosphotyrosine448.9CTNNB1, PIK3CA, BRCA1, ERBB2, CDH1
24guanine44 24 1110.9ERBB2, PARK2, BRCA1, AKT1, CTNNB1
25etoposide44 50 60 1111.8PIK3CA, BRCA1, ERBB2, CDH1, AKT1
26glutamine448.8PARK2, AKT1, CTNNB1, BRCA1, CDH1
27phosphoinositide448.7PARK2, PIK3CA, KRAS, CTNNB1, AKT1
28gefitinib44 50 1110.6PIK3CA, KRAS, AKT1, CTNNB1, ERBB2, CDH1
29tamoxifen44 50 28 1111.6BRCA1, CTNNB1, CDH1, ERBB2, AKT1, PIK3CA
30rapamycin448.6AKT1, ERBB2, KRAS, CTNNB1, CDH1, PIK3CA
31ly294002448.6PIK3CA, ERBB2, AKT1, KRAS, CDH1, CTNNB1
32wortmannin448.6ERBB2, AKT1, KRAS, CTNNB1, CDH1, PIK3CA
33doxorubicin44 50 1110.6PIK3CA, CTNNB1, BRCA1, ERBB2, AKT1, CDH1
34genistein44 28 60 1 24 1113.6BRCA1, CDH1, CTNNB1, PIK3CA, ERBB2, AKT1
35progesterone44 28 60 24 1112.6BRCA1, ERBB2, CDH1, CTNNB1, PIK3CA
36paraffin448.5AKT1, ERBB2, BRCA1, CDH1, CTNNB1, KRAS
37alanine448.5CTNNB1, ERBB2, AKT1, PARK2, BRCA1, CDH1
385fluorouracil448.5BRCA1, CTNNB1, CDH1, KRAS, ERBB2, PIK3CA
39testosterone44 60 24 1111.2BRCA1, PARK2, AKT1, ERBB2, PIK3CA, CTNNB1
40retinoic acid44 249.1BRCA1, KRAS, PIK3CA, CDH1, CTNNB1, AKT1
41cisplatin44 50 60 1111.1CTNNB1, BRCA1, KRAS, PIK3CA, AKT1, ERBB2
42phosphatidylinositol448.1KRAS, CTNNB1, PIK3CA, BRCA1, CDH1, AKT1
43h2o2448.0CTNNB1, ERBB2, AKT1, PARK2, BRCA1, PIK3CA
44gtp44 289.0PARK2, PIK3CA, KRAS, CTNNB1, RRAS2, AKT1
45agar447.8CDH1, PIK3CA, RRAS2, BRCA1, CTNNB1, ERBB2
46paclitaxel44 50 119.7BRCA1, PARK2, AKT1, KRAS, CDH1, CTNNB1
47vegf447.7BRCA1, CDH1, CTNNB1, KRAS, ERBB2, AKT1
48estrogen447.7CDH1, KRAS, ERBB2, AKT1, PARK2, CTNNB1
49serine446.9CDH1, KRAS, ERBB2, AKT1, PARK2, RRAS2
50tyrosine446.9BRCA1, AKT1, CTNNB1, CDH1, KRAS, ERBB2

GO Terms for genes affiliated with Ovarian Cancer, Somatic

About this section

Cellular components related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1catenin complexGO:001634210.0CTNNB1, CDH1
2lateral plasma membraneGO:00163289.9CTNNB1, CDH1
3cell-cell adherens junctionGO:00059139.8CTNNB1, CDH1
4aggresomeGO:00162359.8PARK2, CDH1
5basolateral plasma membraneGO:00163239.6CTNNB1, CDH1, ERBB2
6cytoplasmic side of plasma membraneGO:00098989.6CTNNB1, CDH1
7perinuclear region of cytoplasmGO:00484719.3PARK2, ERBB2, CDH1, CTNNB1
8plasma membraneGO:00058866.7CTNNB1, PIK3CA, RRAS2, BRCA1, AKT1, ERBB2

Biological processes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1regulation of protein localization to cell surfaceGO:0200000810.2CDH1, CTNNB1
2regulation of angiogenesisGO:004576510.0CTNNB1, ERBB2
3negative regulation of release of cytochrome c from mitochondriaGO:00902019.9PARK2, AKT1
4striated muscle cell differentiationGO:00511469.8KRAS, AKT1
5positive regulation of nitric-oxide synthase activityGO:00510009.8AKT1, KRAS
6cellular response to indole-3-methanolGO:00716819.7BRCA1, CDH1, CTNNB1
7protein kinase B signalingGO:00434919.7PIK3CA, AKT1
8positive regulation of MAP kinase activityGO:00434069.6ERBB2, KRAS
9protein autoubiquitinationGO:00518659.5BRCA1, PARK2
10phosphatidylinositol-mediated signalingGO:00480159.5PIK3CA, AKT1, ERBB2
11positive regulation of protein phosphorylationGO:00019349.5KRAS, ERBB2, AKT1
12androgen receptor signaling pathwayGO:00305219.4BRCA1, CTNNB1
13negative regulation of neuron apoptotic processGO:00435249.4PIK3CA, PARK2, KRAS
14insulin receptor signaling pathwayGO:00082869.3AKT1, PIK3CA, KRAS
15apoptotic processGO:00069159.1CDH1, AKT1, BRCA1, CTNNB1
16fibroblast growth factor receptor signaling pathwayGO:00085439.1KRAS, ERBB2, AKT1, PIK3CA
17Fc-epsilon receptor signaling pathwayGO:00380959.1ERBB2, AKT1, PIK3CA, KRAS
18epidermal growth factor receptor signaling pathwayGO:00071739.1AKT1, ERBB2, KRAS, PIK3CA
19neurotrophin TRK receptor signaling pathwayGO:00480119.1KRAS, ERBB2, AKT1, PIK3CA
20protein ubiquitinationGO:00165679.1BRCA1, PARK2, AKT1
21innate immune responseGO:00450878.8CTNNB1, AKT1, KRAS, ERBB2, PIK3CA

Molecular functions related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1kinase bindingGO:00199009.8CTNNB1, PARK2
2protein phosphatase bindingGO:00199039.6ERBB2, CDH1, CTNNB1
3androgen receptor bindingGO:00506819.6BRCA1, CTNNB1
4kinase activityGO:00163019.3PIK3CA, AKT1
5enzyme bindingGO:00198999.3CTNNB1, AKT1, BRCA1
6protein bindingGO:00055155.9CTNNB1, PIK3CA, RRAS2, BRCA1, PARK2, PALB2

Sources for Ovarian Cancer, Somatic

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet